Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study

Table 3 Baseline lipids for DFS

Lipids	N (%)	Number of events	DFS (months), median and range	P value
Cholesterol^a				0.132
High	105 (89.7)	66	80.43 (7.80-81.17)
Low	12 (10.3)	5	29.33 (0.70-85.47)
Triglyceride^a				0.0529
High	34 (29.1)	25	25.05 (1.70–83.8)
Low	83 (70.9)	46	44.50 (0.70-85.47)
HDL-C^a				0.0005
High	24 (20.5)	7	Unmature (5.83–82.13)
Low	93 (79.5)	64	26.30 (0.70-85.47)
LDL-C^a				0.0520
High	101 (86.3)	59	37.80 (0.70-85.47)
Low	16 (13.7)	12	14.75 (3.23–64.63)
ApoA-I^a				0.252
High	102 (87.2)	65	30.20 (0.70-82.33)
Low	15 (12.8)	6	Unmature (4.60-85.47)
ApoB^a				0.0316
High	103 (88.0)	61	37.80 (0.70-85.47)
Low	14 (12.0)	11	11.83 (3.23–63.37)

Abbreviations: DFS disease free survival, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ApoA-I apolipoprotein A-I, ApoB apolipoprotein B
^aComparison between baseline lipids of high and low

ISSN: 1476-511X